FDA halts the use of GSK's Covid-19 drug completely as BA.2 subvariant blankets the country
It only took the Omicron BA.2 subvariant three business days to go from shutting down GlaxoSmithKline and Vir Biotechnology’s Covid-19 treatment sotrovimab in 22 states …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
